A report generated by leading market research firm IMARC Group concludes that there has been a significant transformation in the treatment landscape for malignant mesothelioma. The group anticipates that investment in mesothelioma treatments will more than double over the next ten years from $464.2 million in 2024 to $972 million by 2035. They say that the increase is driven by a shift from offering palliative care to a focus on targeted therapies.
Innovation Driving Shift in Mesothelioma Treatment Strategies
According to the report, there has been a marked increase in understanding of the genetic and molecular underpinnings of malignant mesothelioma. The combination of this greater knowledge of the asbestos-related disease innovations in immunotherapy, targeted therapy, and precision medicine have led to a rapid expansion in the way that physicians are approaching the disease.
Scientists searching for better treatments for malignant mesothelioma have incorporated gene therapies and immunotherapies with traditional approaches like surgery, radiation, and chemotherapy. This multi-faceted attack on the disease, along with greater uptake of personalized treatment strategies, has produced hope for better outcomes, longer survival, and improved quality of life.
Mesothelioma Biomarkers Facilitate Personalized Approach
According to the report, technological innovations in both advanced genomic sequencing and Artificial Intelligence have facilitated better use of personalized medicine and the discovery of new drugs. As information is expanding exponentially, it is anticipated that clinical trials will increasingly focus on using new forms of delivery, as well as immunotherapies and targeted therapies that aim at genetic defects that play a role in the disease.
The news is encouraging for mesothelioma patients and those at risk for the disease, as the report concludes, “Sustained progress in research and development would change mesothelioma from being predominantly untreatable and terminally ill into an area where the patients can expect reasonable long-term treatment options and thus better quality of life.”
If you or someone you love has been diagnosed with malignant mesothelioma or another asbestos-related disease, the Patient Advocates at Mesothelioma.net can help. Call us today at 1-800-692-8608 to learn more.
